Thrombosis in cancer patients: Etiology, incidence, and management

Rahul A. Sheth; Andrew Niekamp; Keith B. Quencer; Fadi Shamoun; Martha Gracia Knuttinen; Sailendra Naidu; Rahmi Oklu

doi:10.21037/cdt.2017.11.02

Thrombosis in cancer patients: Etiology, incidence, and management

Rahul A. Sheth, Andrew Niekamp, Keith B. Quencer, Fadi Shamoun, Martha Gracia Knuttinen, Sailendra Naidu, Rahmi Oklu

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Venous thromboembolism (VTE) is the second most common cause of mortality in cancer patients. The mechanisms of cancer-associated thrombosis (CAT), much like cancer itself, are multi-factorial and incompletely understood. Cancer type, stage, tumor-derived factors and genetics all affect CAT risk. Furthermore, cancer therapies as well as the indwelling vascular devices through which these therapies are delivered can increase the risk for CAT. In this review, we summarize mechanisms of hypercoagulability in cancer patients, patterns of thrombosis associated with cancer, current guidelines for the diagnosis and management of CAT, and important considerations regarding the placement of implantable vascular devices in the care of cancer patients with VTE.

Original language	English (US)
Pages (from-to)	S178-S185
Journal	Cardiovascular Diagnosis and Therapy
Volume	7
DOIs	https://doi.org/10.21037/cdt.2017.11.02
State	Published - Dec 1 2017

Keywords

Anticoagulation
Cancer
Venous access catheters
Venous thrombosis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.21037/cdt.2017.11.02

Cite this

@article{a1450852e4264136beb1bc65d18d4378,

title = "Thrombosis in cancer patients: Etiology, incidence, and management",

abstract = "Venous thromboembolism (VTE) is the second most common cause of mortality in cancer patients. The mechanisms of cancer-associated thrombosis (CAT), much like cancer itself, are multi-factorial and incompletely understood. Cancer type, stage, tumor-derived factors and genetics all affect CAT risk. Furthermore, cancer therapies as well as the indwelling vascular devices through which these therapies are delivered can increase the risk for CAT. In this review, we summarize mechanisms of hypercoagulability in cancer patients, patterns of thrombosis associated with cancer, current guidelines for the diagnosis and management of CAT, and important considerations regarding the placement of implantable vascular devices in the care of cancer patients with VTE.",

keywords = "Anticoagulation, Cancer, Venous access catheters, Venous thrombosis",

author = "Sheth, {Rahul A.} and Andrew Niekamp and Quencer, {Keith B.} and Fadi Shamoun and Knuttinen, {Martha Gracia} and Sailendra Naidu and Rahmi Oklu",

note = "Publisher Copyright: {\textcopyright} 2017 Cardiovascular Diagnosis and Therapy.",

year = "2017",

month = dec,

day = "1",

doi = "10.21037/cdt.2017.11.02",

language = "English (US)",

volume = "7",

pages = "S178--S185",

journal = "Cardiovascular Diagnosis and Therapy",

issn = "2223-3652",

publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Thrombosis in cancer patients

T2 - Etiology, incidence, and management

AU - Sheth, Rahul A.

AU - Niekamp, Andrew

AU - Quencer, Keith B.

AU - Shamoun, Fadi

AU - Knuttinen, Martha Gracia

AU - Naidu, Sailendra

AU - Oklu, Rahmi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Venous thromboembolism (VTE) is the second most common cause of mortality in cancer patients. The mechanisms of cancer-associated thrombosis (CAT), much like cancer itself, are multi-factorial and incompletely understood. Cancer type, stage, tumor-derived factors and genetics all affect CAT risk. Furthermore, cancer therapies as well as the indwelling vascular devices through which these therapies are delivered can increase the risk for CAT. In this review, we summarize mechanisms of hypercoagulability in cancer patients, patterns of thrombosis associated with cancer, current guidelines for the diagnosis and management of CAT, and important considerations regarding the placement of implantable vascular devices in the care of cancer patients with VTE.

AB - Venous thromboembolism (VTE) is the second most common cause of mortality in cancer patients. The mechanisms of cancer-associated thrombosis (CAT), much like cancer itself, are multi-factorial and incompletely understood. Cancer type, stage, tumor-derived factors and genetics all affect CAT risk. Furthermore, cancer therapies as well as the indwelling vascular devices through which these therapies are delivered can increase the risk for CAT. In this review, we summarize mechanisms of hypercoagulability in cancer patients, patterns of thrombosis associated with cancer, current guidelines for the diagnosis and management of CAT, and important considerations regarding the placement of implantable vascular devices in the care of cancer patients with VTE.

KW - Anticoagulation

KW - Cancer

KW - Venous access catheters

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85038629405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038629405&partnerID=8YFLogxK

U2 - 10.21037/cdt.2017.11.02

DO - 10.21037/cdt.2017.11.02

M3 - Review article

AN - SCOPUS:85038629405

SN - 2223-3652

VL - 7

SP - S178-S185

JO - Cardiovascular Diagnosis and Therapy

JF - Cardiovascular Diagnosis and Therapy

ER -

Thrombosis in cancer patients: Etiology, incidence, and management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this